Médicaments en développement en 2009 pour les cancers du poumon
SciMedWeb
● 1572932A Phase III
● Abraxane (albumin-bound paclitaxel) Phase III
● ABT-263 Phase I/II
● ABT-751 Phase II
● ABT-869 Phase II
● Actimid (pomalidomide) Phase I/II
● Advexin (contusugene ladenovec ) Phase II
● aflibercept (VEGF-trap) Phase III
● Alimta (pemetrexed) Phase III
● AMG 102 Phase I/II
● AMG 479 Phase II
● Amplimexon (imexon) Phase I
● amrubicin Phase III
● ANZ-207 Phase I
● apomab Phase II
● Armala (pazopanib) Phase II
● ARQ-197 Phase I/II
● AT-101 Phase II
● AV-951 Phase I/II
● Avastin (bevacizumab) Phase II
● axitinib Phase II
● AZD6244 Phase II
● belinostat Phase II
● BIBF 1120 Phase III
● BIBW 2992 Phase II/III
● BMS-690514 (ErbB/VEGF receptor inhibitor)
● Camptosar (irinotecan)
● canertinib Phase II
● Capoxigem (apricoxib) Phase II
● CBP501 Phase II
● cisplatin liposomal Phase II
● conatumumab Phase I/II
● CP-751871 Phase III
● CS-1017 Phase II
● deforolimus (MK-8669) Phase II
● diflomotecan Phase II
● DMXAA Phase III
● doxorubicin inhaled Phase II
● EC-145 Phase II
● Erbitux (cetuximab) Phase III
● eribulin mesylate (E7389)Phase II
● Gemzar (gemcitabine) Phase II
● Genasense (oblimersen) Phase II/III
● GI-4000 Phase II
● glufosfamide Phase II
● GRN-163L Phase I
● Hycamtin (topotecan) Phase III
● HyperAcute lung cancer vaccine Phase I/II
● IMC-1121B Phase II
● IMC-A12 Phase II
● IMGN-901 Phase II
● IMO-2055 Phase I
● INGN 225 (p53 vaccine) Phase II
● INGN 401 (nano-FUS-1) Phase I
● Ixempra (ixabepilone)
● JNJ-26854165 Phase I
● Karenitecin (cositecan) Phase II
● Levulan (aminolevulinic acid)
● Lucanix (belagenpumatucel-L) Phase III
● lung cancer vaccine (NY-ESO-1) Phase I
● mapatumumab Phase II
● milataxel Phase II
● MK-0646 Phase I/II
● MKC 1 Phase II
● MORAb-009 Phase II
● motesanib Phase III
● naptumomab (estafenatox) Phase I
● neratinib (HKI272) Phase II
● Nexavar (sorafenib) Phase III
● NOV-002 Phase III
● NPI-2358 Phase I
● obatoclax Phase I/II
● OBP-301 Phase I
● OGX-011 (ISIS-112989) Phase I/II
● OGX-427 Phase I
● Onconase (ranpirnase) Phase III
● Opaxio (paclitaxel poliglumex) Phase III
● P-2045 Phase I
● patupilone (EPO906) Phase II
● pelitinib (EKB569) Phase II
● PF-299804 Phase II
● picoplatin Phase II
● plitidepsin Phase II
● PR-104 Phase II
● pralatrexate (PDX) Phase II
● ProMune (agatolimod) Phase II
● PS-095760 Phase II
● R1454 Phase I
● R1507 Phase II
● Reolysin (reovirus) Phase II
● retaspimycin (IPI 504) Phase II
● S-1 Phase II
● salirasib Phase II
● sapacitabine Phase II
● satraplatin Phase II
● SCH-58500 (p53 gene therapy) Phase II
● SCH-727965 Phase II
● seliciclib Phase II
● sibrotuzumab Phase II
● SNDX-275 Phase I/II
● Stimuvax (BLP25 liposomal cancer vaccine) Phase III
● Sutent (sunitinib) Phase III
● talactoferrin Phase III
● Tarceva (erlotinib) Phase III
● Telcyta (canfosfimide) Phase III
● Temodar (temozolomide) Phase II
● TG-4010 Phase I
● Thymitaq (nolatrexed) Phase II
● topotecan liposomal Phase I
● Torisel (temsirolimus) Phase II
● tremelimumab Phase II
● Triapine Phase II
● tucotuzumab (celmoleukin) Phase II
● Vectibix (panitumumab) Phase II
● Velcade (bortezomib) Phase II
● volociximab Phase II
● Xcytrin (motexafin gadolinium ) Phase II
● XL-647 Phase II
● Zactima (vandetanib) Phase III
● Zolinza (vorinostat) Phase III
● Zybrestat (fosbretabulin) Phase II
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)